Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed Hairy Cell Leukemia
NCT01841723Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2013
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 32 weeks. Started Apr 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT01841723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01841723.